Published in Chem Biol Drug Des on September 16, 2015
Probing the mechanism of cardiovascular drugs using a covalent levosimendan analog. J Mol Cell Cardiol (2016) 0.75
Changes in the Dynamics of the Cardiac Troponin C Molecule Explain the Effects of Ca(2+)-Sensitizing Mutations. J Biol Chem (2017) 0.75
Dynamic Equilibrium of cTnC's Hydrophobic Cleft and Its Modulation by Ca2+ Sensitizers and a Ca2+ Sensitivity blunting phosphomimic, cTnT(T204E). Bioconjug Chem (2017) 0.75
Regulation of contraction in striated muscle. Physiol Rev (2000) 9.40
Purification of muscle actin. Methods Enzymol (1982) 9.11
Structure of the core domain of human cardiac troponin in the Ca(2+)-saturated form. Nature (2003) 4.71
The troponin complex and regulation of muscle contraction. FASEB J (1995) 2.64
Preparation and identification of alpha- and beta-tropomyosins. Methods Enzymol (1982) 2.11
Identification of a functionally critical protein kinase C phosphorylation residue of cardiac troponin T. J Biol Chem (2003) 1.99
Calcium-induced structural transition in the regulatory domain of human cardiac troponin C. Biochemistry (1997) 1.61
Thin filament mutations: developing an integrative approach to a complex disorder. Circ Res (2011) 1.55
Interaction of levosimendan with cardiac troponin C in the presence of cardiac troponin I peptides. J Mol Cell Cardiol (2003) 1.54
Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation (2006) 1.53
Conformation of the regulatory domain of cardiac muscle troponin C in its complex with cardiac troponin I. J Biol Chem (1999) 1.43
Troponin: structure, properties, and mechanism of functioning. Biochemistry (Mosc) (1999) 1.35
Switching of troponin I: Ca(2+) and myosin-induced activation of heart muscle. J Mol Biol (2004) 1.25
Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol (2011) 1.24
Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation (1998) 1.20
Structural kinetics of cardiac troponin C mutants linked to familial hypertrophic and dilated cardiomyopathy in troponin complexes. J Biol Chem (2007) 1.20
Structure of the regulatory N-domain of human cardiac troponin C in complex with human cardiac troponin I147-163 and bepridil. J Biol Chem (2002) 1.19
Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem (1994) 1.17
Ca2+-induced conformational transition in the inhibitory and regulatory regions of cardiac troponin I. J Biol Chem (2003) 1.14
Sensitization of dog and guinea pig heart myofilaments to Ca2+ activation and the inotropic effect of pimobendan: comparison with milrinone. Circ Res (1988) 1.13
Structure of the C-domain of human cardiac troponin C in complex with the Ca2+ sensitizing drug EMD 57033. J Biol Chem (2001) 1.13
Coupling of adjacent tropomyosins enhances cross-bridge-mediated cooperative activation in a markov model of the cardiac thin filament. Biophys J (2010) 1.11
Effects of PKA phosphorylation of cardiac troponin I and strong crossbridge on conformational transitions of the N-domain of cardiac troponin C in regulated thin filaments. Biochemistry (2007) 1.11
Cardiac Ca2+ signaling and Ca2+ sensitizers. Circ J (2008) 1.11
The role of troponins in muscle contraction. IUBMB Life (2002) 1.10
Removal of the cardiac troponin I N-terminal extension improves cardiac function in aged mice. J Biol Chem (2010) 1.07
Bepridil opens the regulatory N-terminal lobe of cardiac troponin C. Proc Natl Acad Sci U S A (2000) 1.05
Ca(2+) induces an extended conformation of the inhibitory region of troponin I in cardiac muscle troponin. J Mol Biol (2001) 1.05
Kinetics of conformational transitions in cardiac troponin induced by Ca2+ dissociation determined by Förster resonance energy transfer. J Biol Chem (2003) 1.04
Förster resonance energy transfer structural kinetic studies of cardiac thin filament deactivation. J Biol Chem (2009) 1.03
Interaction of cardiac troponin with cardiotonic drugs: a structural perspective. Biochem Biophys Res Commun (2007) 1.01
Conformation of the N-terminal segment of a monocysteine mutant of troponin I from cardiac muscle. Biochemistry (1997) 1.00
A structural and functional perspective into the mechanism of Ca2+-sensitizers that target the cardiac troponin complex. J Mol Cell Cardiol (2010) 1.00
Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J Biol Chem (2000) 0.98
Different effect of the Ca(2+) sensitizers EMD 57033 and CGP 48506 on cross-bridge cycling in human myocardium. J Pharmacol Exp Ther (2000) 0.97
Expression of cardiac troponin T with COOH-terminal truncation accelerates cross-bridge interaction kinetics in mouse myocardium. Am J Physiol Heart Circ Physiol (2004) 0.97
Binding of a calcium sensitizer, bepridil, to cardiac troponin C. A fluorescence stopped-flow kinetic, circular dichroism, and proton nuclear magnetic resonance study. J Biol Chem (1990) 0.96
Interaction of cardiac troponin C with Ca(2+) sensitizer EMD 57033 and cardiac troponin I inhibitory peptide. Biochemistry (2000) 0.96
Structural dynamics of C-domain of cardiac troponin I protein in reconstituted thin filament. J Biol Chem (2011) 0.94
Stereoselective binding of levosimendan to cardiac troponin C causes Ca2+-sensitization. Eur J Pharmacol (2004) 0.93
Defining the binding site of levosimendan and its analogues in a regulatory cardiac troponin C-troponin I complex. Biochemistry (2008) 0.92
Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium. Eur J Pharmacol (2000) 0.90
UD-CG 115--a cardiotonic pyridazinone which elevates cyclic AMP and prolongs the action potential in guinea-pig papillary muscle. Naunyn Schmiedebergs Arch Pharmacol (1984) 0.89
Mechanism of action of Ca2+ sensitizers--update 2001. Cardiovasc Drugs Ther (2001) 0.89
Conformation of the troponin core complex in the thin filaments of skeletal muscle during relaxation and active contraction. J Mol Biol (2012) 0.88
Effects of OR-1896, a metabolite of levosimendan, on force of contraction and Ca2+ transients under acidotic condition in aequorin-loaded canine ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol (2002) 0.86
Drug binding to cardiac troponin C. J Biol Chem (1999) 0.85
Enantiomeric dissection of the effects of the inotropic agent, EMD 53998, in single cardiac myocytes. Am J Physiol (1993) 0.84
A computational and experimental approach to investigate bepridil binding with cardiac troponin. J Phys Chem B (2011) 0.81
Interaction of bepridil with the cardiac troponin C/troponin I complex. FEBS Lett (2001) 0.81
Levosimendan improves contractility in vivo and in vitro in a rodent model of post-myocardial infarction heart failure. Acta Physiol (Oxf) (2014) 0.81
FRET study of the structural and kinetic effects of PKC phosphomimetic cardiac troponin T mutants on thin filament regulation. Arch Biochem Biophys (2014) 0.78